Press Release | Nov 13, 2024Honigman Advises Catalio Capital Management in its investment in Alentis Therapeutics’ $181.4 Million Series D Financing

Honigman advised Catalio Capital Management (Catalio) in its participation in Alentis Therapeutics' (Alentis) $181.4 million Series D financing. Based in Allschwil, Basel-Country since 2019, Alentis is a clinical stage biotechnology company on a mission to develop first-in-class antibodies and ADCs for CLDN1+ tumors and organ fibrosis. Headquartered in New York, New York since 2020, Catalio is a multi-strategy investment firm focused on breakthrough biomedical technology and innovative healthcare companies.

As a key investor in the Series D round, Catalio Capital Management will work alongside the other syndicate participants to support Alentis' innovative pipeline of Claudin-1 (CLDN1) targeted antibody-drug conjugates (ADCs) for solid tumors and organ fibrosis.

This significant investment round was led by OrbiMed, with co-leads Novo Holdings and Jeito Capital, and supported by other top-tier biotech investors, including Catalio Capital Management, Frazier Life Sciences, Longitude Capital, Piper Heartland Healthcare Capital, and Avego Bioscience Capital. The round also saw significant support from existing investor RA Capital Management, along with contributions from Morningside Venture Investments, BB Pureos, Bpifrance through its InnoBio 2 fund, and several other early-stage institutional investors.

Read the transaction press release

The Honigman team was led by corporate partners Phillip D. Torrence, Paul Wellington and Andrew Weber alongside associate Rachel Rhodes.

About Honigman
Honigman is an Am Law 200 full-service, general business law firm with more than 350 attorneys in Chicago, Michigan (Ann Arbor, Bloomfield Hills, Detroit, Grand Rapids, Kalamazoo and Lansing), Washington, D.C. and its newest office in Israel (through its wholly owned subsidiary, Honigman Law Israel). Honigman lawyers counsel clients on complex issues in more than 60 areas of law. For more information, visit www.honigman.com.

###